176
Participants
Start Date
June 21, 2018
Primary Completion Date
June 30, 2022
Study Completion Date
June 30, 2022
MesoPher
Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
University Hospital Antwerp, Antwerp
Centre Hospitalier Régional Universitaire de Lille, Lille
Universitá Politecnica delle Marche - Ospedali Riuniti di Ancona, Ancona
Netherlands Cancer Institue, Amsterdam
Erasmus Medical Centre, Rotterdam
University of Leicester, Leicester
Lead Sponsor
TMC Pharma
UNKNOWN
Amphera BV
INDUSTRY